US health agency raises ‘concern’ over AstraZeneca trial data
The National Institute of Allergy and Infectious Diseases says a monitoring board has 'expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data'.